Compare Celsius Holdings, Inc. (CELH) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Mesoblast Limited — how do they compare? Celsius Holdings, Inc. trades at $30.91 (market cap $7.71B), while Mesoblast Limited trades at $18.05 (market cap $2.12B). The key difference: Celsius Holdings, Inc. is far larger — about 3.6× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | MESO | |
|---|---|---|
Market Cap | $7.71B | $2.12B |
Sector | Consumer Staples | Technology |
52-Week High | $64.86 | $20.96 |
52-Week Low | $27.75 | $10.96 |
Enterprise Value | $9.58B | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Celsius Holdings (CELH) trades at $29.83, down 2.52% on the day, amid bearish technical signals despite strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $2.52B, though net margins have compressed to 4.29%. Recent quarters consistently beat EPS estimates, but cash flow turned negative due to heavy investing activity. Legal investigations and competitive pressures weigh on sentiment, while a $52.30 consensus price target implies significant upside.
Outlook remains bifurcated: high growth potential and international expansion contrast with margin pressure and litigation risks. Investors face a volatile growth story where execution on profitability and market share gains will dictate performance. The stock's high P/E of 71.16 demands sustained earnings acceleration to justify valuation.
MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.
The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
